

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/256434 A1

(51) International Patent Classification:

A61P 31/14 (2006.01) C07D 401/14 (2006.01)
C07D 207/267 (2006.01) C07D 403/12 (2006.01)
C07D 209/42 (2006.01) C07D 403/14 (2006.01)
C07D 401/12 (2006.01) C07D 417/14 (2006.01)

(21) International Application Number:

PCT/US2022/031815

(22) International Filing Date:

01 June 2022 (01.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/195,930 02 June 2021 (02.06.2021) US
63/275,113 03 November 2021 (03.11.2021) US

(71) Applicant: **ACEA THERAPEUTICS, INC.** [US/US];
4955 Directors Place, San Diego, California 92121 (US).

(72) Inventors: **MAO, Long**; 4955 Directors Place, San Diego,
California 92121 (US). **XU, Xiao**; 4955 Directors Place,
San Diego, California 92121 (US). **SHAABANI, Namir**;
4955 Directors Place, San Diego, California 92121 (US).
JIN, Can; 4955 Directors Place, San Diego, California
92121 (US).

(74) Agent: **BREIER, Adam M.** et al.; McNeill Baur PLLC,
125 Cambridge Park Drive, Suite 301, Cambridge, Massa-
chusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,


NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PROTEASE INHIBITORS AS ANTIVIRALS



(57) Abstract: Provided herein, *inter alia*, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

WO 2022/256434 A1